Mutual Termination of License and Development Agreements between Health Discovery Corporation and Abbott Molecular, Quest Diagnostics, and SmartPerMed
Contract Categories:
Business Operations
›
Termination Agreements
Summary
Health Discovery Corporation, Abbott Molecular, Quest Diagnostics, and SmartPerMed have mutually agreed to terminate their Prostate Cancer and Breast Cancer License and Development Agreements. As of September 28, 2012, all parties confirm that these agreements are officially ended. Abbott Molecular and Quest Diagnostics no longer have any rights or obligations under the terminated agreements, and no further payments are required. This termination is effective immediately and is acknowledged by all involved parties.
EX-10.2 3 ex10-2.htm EXHIBIT 10.2 ex10-2.htm
EXHIBIT 10.2
Health Discovery Corporation
2 East Bryan Street, Suite 1500
Savannah, Georgia 31401
September 28, 2012
Stafford O’Kelly
| Abbott Molecular | VIA Email |
Stafford,
Health Discovery Corporation has received your notice that Abbott Molecular is not interested in moving forward with the Prostate Cancer License and Development Agreements. It is our understanding that this results in a termination of these Agreements and we are in agreement with you and want to terminate the Agreements as well. Let this notice serve that the Agreements are now officially jointly terminated and that Abbott Molecular no longer has any rights granted to them under these Agreements.
Sincerely,
| /s/ Stephen D. Barnhill, M.D. | |
Stephen D. Barnhill, M.D.
Chairman and Chief Executive Officer
Health Discovery Corporation
Health Discovery Corporation
2 East Bryan Street, Suite 1500
Savannah, Georgia 31401
September 28, 2012
Nicholas Conti
| Quest Diagnostics | VIA Email |
Nick,
Health Discovery Corporation has received your notice that Quest Diagnostics is not interested in moving forward with the Prostate Cancer License and Development Agreements and not making any additional payments required under such Agreements. It is our understanding that this results in a termination of these Agreements and we are in agreement with you and want to terminate the Agreements as well. Let this notice serve that the Agreements are now officially jointly terminated and that Quest Diagnostics no longer has any rights granted to them under these Agreements nor does Quest Diagnostics have any additional obligations under such Agreements.
Sincerely,
| /s/ Stephen D. Barnhill, M.D. | |
Stephen D. Barnhill, M.D.
Chairman and Chief Executive Officer
Health Discovery Corporation
Health Discovery Corporation
2 East Bryan Street, Suite 1500
Savannah, Georgia 31401
September 28, 2012
Nicholas Conti
| Quest Diagnostics | VIA Email |
Nick,
Health Discovery Corporation and SmartPerMed have received your notice that Quest Diagnostics is not interested in moving forward with the Breast Cancer License and Development Agreements and not making any additional payments required under such Agreements. It is our understanding that this results in a termination of these Agreements and we are in agreement with you and want to terminate the Agreements as well. Let this notice serve that the Agreements are now officially jointly terminated and that Quest Diagnostics no longer has any rights granted to them under these Agreements nor does Quest Diagnostics have any additional obligations under such Agreements.
Sincerely,
| /s/ Stephen D. Barnhill, M.D. | |
Stephen D. Barnhill, M.D.
Chairman and Chief Executive Officer
Health Discovery Corporation
